NEW YORK, Oct. 7-Celera Diagnostics said today that it had struck a deal with Bristol-Myers Squibb to develop drugs and diagnostics for cardiovascular disease and diabetes.
Bristol-Myers will provide more than 3,000 clinical samples from its cholesterol-lowering drug studies to Celera Diagnostics, which will study the prevalence of roughly 1,000 SNPs in this population. By correlating these SNPs with clinical data and drug response, the companies hope to identify therapeutic targets.
The pharmaceutical company will develop and market drugs based on these targets; Celera will retain rights for diagnostic products.
A steering committee will manage the collaboration. Financial terms were not disclosed.